Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Perusini MA, Novitzky-Basso I, Atenafu EG, Forrest D, Bence-Bruckler I, Savoie L, Keating MM, Busque L, Delage R, Xenocostas A, Liew E, Laneuville P, Paulson K, Stockley T, Lipton JH, Leber B, Kim DDH. Perusini MA, et al. Br J Haematol. 2023 Dec;203(5):781-791. doi: 10.1111/bjh.19058. Epub 2023 Sep 11. Br J Haematol. 2023. PMID: 37697469
Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.
Perusini MA, Andrews C, Atenafu EG, Gupta V, Maze D, Schuh AC, Yee KW, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Sibai J, Schimmer AD, Minden MD, Sibai H. Perusini MA, et al. Hematology. 2024 Dec;29(1):2329027. doi: 10.1080/16078454.2024.2329027. Epub 2024 Mar 25. Hematology. 2024. PMID: 38526239
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol.
Perusini MA, Andrews C, Eshetu AG, Gupta V, Maze D, Yee KWL, Bankar A, Davidson MB, Richard-Carpentier G, Chan SM, Schimmer AD, Sibai J, Alharbi S, Lucero JA, Linn SM, Minden MD, Schuh AC, Sibai H. Perusini MA, et al. Leukemia. 2024 Apr;38(4):912-913. doi: 10.1038/s41375-024-02201-1. Epub 2024 Mar 2. Leukemia. 2024. PMID: 38431747 No abstract available.
Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
González JS, Perusini MA, Basquiera AL, Alfonso G, Fantl D, Lima WM, Nucifora E, Lazzarino C, Novoa V, de Andrade Silva MC, Larripa IB, Rocha V, Arbelbide J, Velloso EDRP, Belli CB. González JS, et al. Among authors: perusini ma. Ann Hematol. 2021 Jun;100(6):1439-1449. doi: 10.1007/s00277-021-04539-3. Epub 2021 May 1. Ann Hematol. 2021. PMID: 33932168
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Perusini MA, Žáčková D, Kim T, Pagnano K, Pavlovsky C, Ježíšková I, Kvetková A, Jurček T, Kim J, Yoo Y, Yi S, Lee H, Kim KH, Chang M, Capo-Chichi JM, Medeiros JJF, Arruda A, Minden M, Zhang Z, Abelson S, Mayer J, Hwan Kim DD. Perusini MA, et al. Blood Adv. 2024 May 28;8(10):2361-2372. doi: 10.1182/bloodadvances.2023012127. Blood Adv. 2024. PMID: 38447114 Free PMC article.
Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients.
Lazzarino C, Arbelbide J, Schuster S, Crisp R, González J, Tavares R, Perusini MA, Di Stefano M, Pintos N, Espinosa D, Pimentel M, Rosenhain M, Serrano JC, Enrico A, Iastrebner M, Belli CB. Lazzarino C, et al. Among authors: perusini ma. Am J Hematol. 2020 Dec;95(12):E323-E326. doi: 10.1002/ajh.25987. Epub 2020 Oct 1. Am J Hematol. 2020. PMID: 32864747 Free article. No abstract available.